-
1
-
-
51549117737
-
-
National Cancer Institute, Bethesda, MD
-
Ries L., Melbert D., Krapcho M., Stinchcomb D., Howlader N., Horner M., et al. SEER cancer statistics review, 1975-2005 2008, 1975-2005. National Cancer Institute, Bethesda, MD.
-
(2008)
SEER cancer statistics review, 1975-2005
, pp. 1975-2005
-
-
Ries, L.1
Melbert, D.2
Krapcho, M.3
Stinchcomb, D.4
Howlader, N.5
Horner, M.6
-
2
-
-
83255170962
-
Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia
-
Carballido E., Veliz M., Komrokji R., Pinilla-Ibarz J. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control 2012, 19:54-67.
-
(2012)
Cancer Control
, vol.19
, pp. 54-67
-
-
Carballido, E.1
Veliz, M.2
Komrokji, R.3
Pinilla-Ibarz, J.4
-
3
-
-
84879748062
-
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
-
Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369:32-42.
-
(2013)
N Engl J Med
, vol.369
, pp. 32-42
-
-
Byrd, J.C.1
Furman, R.R.2
Coutre, S.E.3
Flinn, I.W.4
Burger, J.A.5
Blum, K.A.6
-
4
-
-
23044501404
-
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
-
Wierda W., O'Brien S., Wen S., Faderl S., Garcia-Manero G., Thomas D., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4070-4078.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4070-4078
-
-
Wierda, W.1
O'Brien, S.2
Wen, S.3
Faderl, S.4
Garcia-Manero, G.5
Thomas, D.6
-
5
-
-
23044510136
-
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
-
Keating M.J., O'Brien S., Albitar M., Lerner S., Plunkett W., Giles F., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079-4088.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4079-4088
-
-
Keating, M.J.1
O'Brien, S.2
Albitar, M.3
Lerner, S.4
Plunkett, W.5
Giles, F.6
-
6
-
-
19944429446
-
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
-
Byrd J.C., Rai K., Peterson B.L., Appelbaum F.R., Morrison V.A., Kolitz J.E., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105:49-53.
-
(2005)
Blood
, vol.105
, pp. 49-53
-
-
Byrd, J.C.1
Rai, K.2
Peterson, B.L.3
Appelbaum, F.R.4
Morrison, V.A.5
Kolitz, J.E.6
-
7
-
-
0036139106
-
Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed
-
Keating M.J., Cazin B., Coutre S., Birhiray R., Kovacsovics T., Langer W., et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002, 20:205-213.
-
(2002)
J Clin Oncol
, vol.20
, pp. 205-213
-
-
Keating, M.J.1
Cazin, B.2
Coutre, S.3
Birhiray, R.4
Kovacsovics, T.5
Langer, W.6
-
8
-
-
84865997474
-
Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis
-
Kharfan-Dabaja M.A., Pidala J., Kumar A., Terasawa T., Djulbegovic B. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplant 2012, 47:1164-1170.
-
(2012)
Bone Marrow Transplant
, vol.47
, pp. 1164-1170
-
-
Kharfan-Dabaja, M.A.1
Pidala, J.2
Kumar, A.3
Terasawa, T.4
Djulbegovic, B.5
-
9
-
-
0025757084
-
Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG
-
Michallet M., Corront B., Hollard D., Gratwohl A., Milpied N., Dauriac C., et al. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG. Bone Marrow Transplant 1991, 7:275-279.
-
(1991)
Bone Marrow Transplant
, vol.7
, pp. 275-279
-
-
Michallet, M.1
Corront, B.2
Hollard, D.3
Gratwohl, A.4
Milpied, N.5
Dauriac, C.6
-
10
-
-
0030795881
-
Induction of graft-versus-leukemia effect in a patient with chronic lymphocytic leukemia
-
deMagalhaes-Silverman M., Donnenberg A., Hammert L., Lister J., Myers D., Simpson J., et al. Induction of graft-versus-leukemia effect in a patient with chronic lymphocytic leukemia. Bone Marrow Transplant 1997, 20:175-177.
-
(1997)
Bone Marrow Transplant
, vol.20
, pp. 175-177
-
-
deMagalhaes-Silverman, M.1
Donnenberg, A.2
Hammert, L.3
Lister, J.4
Myers, D.5
Simpson, J.6
-
11
-
-
27744580700
-
Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease
-
Toze C.L., Galal A., Barnett M.J., Shepherd J.D., Conneally E.A., Hogge D.E., et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant 2005, 36:825-830.
-
(2005)
Bone Marrow Transplant
, vol.36
, pp. 825-830
-
-
Toze, C.L.1
Galal, A.2
Barnett, M.J.3
Shepherd, J.D.4
Conneally, E.A.5
Hogge, D.E.6
-
12
-
-
85014257001
-
Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia
-
Dreger P., Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002, 16:985-992.
-
(2002)
Leukemia
, vol.16
, pp. 985-992
-
-
Dreger, P.1
Montserrat, E.2
-
13
-
-
28844483804
-
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia
-
Gribben J.G., Zahrieh D., Stephans K., Bartlett-Pandite L., Alyea E.P., Fisher D.C., et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005, 106:4389-4396.
-
(2005)
Blood
, vol.106
, pp. 4389-4396
-
-
Gribben, J.G.1
Zahrieh, D.2
Stephans, K.3
Bartlett-Pandite, L.4
Alyea, E.P.5
Fisher, D.C.6
-
14
-
-
84877282791
-
Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies
-
El-Jurdi N., Reljic T., Kumar A., Pidala J., Bazarbachi A., Djulbegovic B., et al. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy 2013, 5:457-466.
-
(2013)
Immunotherapy
, vol.5
, pp. 457-466
-
-
El-Jurdi, N.1
Reljic, T.2
Kumar, A.3
Pidala, J.4
Bazarbachi, A.5
Djulbegovic, B.6
-
15
-
-
0031879197
-
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
-
Khouri I.F., Keating M., Korbling M., Przepiorka D., Anderlini P., O'Brien S., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817-2824.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2817-2824
-
-
Khouri, I.F.1
Keating, M.2
Korbling, M.3
Przepiorka, D.4
Anderlini, P.5
O'Brien, S.6
-
16
-
-
55549097826
-
Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis
-
Schetelig J., van Biezen A., Brand R., Caballero D., Martino R., Itala M., et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008, 26:5094-5100.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5094-5100
-
-
Schetelig, J.1
van Biezen, A.2
Brand, R.3
Caballero, D.4
Martino, R.5
Itala, M.6
-
17
-
-
54449093967
-
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
-
Sorror M.L., Storer B.E., Sandmaier B.M., Maris M., Shizuru J., Maziarz R., et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008, 26:4912-4920.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4912-4920
-
-
Sorror, M.L.1
Storer, B.E.2
Sandmaier, B.M.3
Maris, M.4
Shizuru, J.5
Maziarz, R.6
-
18
-
-
20844436596
-
Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis
-
Dreger P., Brand R., Milligan D., Corradini P., Finke J., Lambertenghi Deliliers G., et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 2005, 19:1029-1033.
-
(2005)
Leukemia
, vol.19
, pp. 1029-1033
-
-
Dreger, P.1
Brand, R.2
Milligan, D.3
Corradini, P.4
Finke, J.5
Lambertenghi Deliliers, G.6
-
19
-
-
83255164801
-
Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens
-
Kharfan-Dabaja M.A., Bazarbachi A. Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens. Cancer Control 2012, 19:68-75.
-
(2012)
Cancer Control
, vol.19
, pp. 68-75
-
-
Kharfan-Dabaja, M.A.1
Bazarbachi, A.2
-
20
-
-
52049122208
-
Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia
-
Kharfan-Dabaja M.A., Chavez J.C., Khorfan K.A., Pinilla-Ibarz J. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. Cancer 2008, 113:897-906.
-
(2008)
Cancer
, vol.113
, pp. 897-906
-
-
Kharfan-Dabaja, M.A.1
Chavez, J.C.2
Khorfan, K.A.3
Pinilla-Ibarz, J.4
-
21
-
-
45149100665
-
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
-
Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
-
(2008)
Blood
, vol.111
, pp. 5446-5456
-
-
Hallek, M.1
Cheson, B.D.2
Catovsky, D.3
Caligaris-Cappio, F.4
Dighiero, G.5
Dohner, H.6
-
22
-
-
33845543049
-
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
-
Dreger P., Corradini P., Kimby E., Michallet M., Milligan D., Schetelig J., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007, 21:12-17.
-
(2007)
Leukemia
, vol.21
, pp. 12-17
-
-
Dreger, P.1
Corradini, P.2
Kimby, E.3
Michallet, M.4
Milligan, D.5
Schetelig, J.6
-
23
-
-
77957664665
-
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
-
Hallek M., Fischer K., Fingerle-Rowson G., Fink A.M., Busch R., Mayer J., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
-
(2010)
Lancet
, vol.376
, pp. 1164-1174
-
-
Hallek, M.1
Fischer, K.2
Fingerle-Rowson, G.3
Fink, A.M.4
Busch, R.5
Mayer, J.6
-
24
-
-
77953556313
-
A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis
-
Perkins J., Field T., Kim J., Kharfan-Dabaja M.A., Fernandez H., Ayala E., et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010, 16:937-947.
-
(2010)
Biol Blood Marrow Transplant
, vol.16
, pp. 937-947
-
-
Perkins, J.1
Field, T.2
Kim, J.3
Kharfan-Dabaja, M.A.4
Fernandez, H.5
Ayala, E.6
-
25
-
-
84870455529
-
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation
-
Pidala J., Kim J., Jim H., Kharfan-Dabaja M.A., Nishihori T., Fernandez H., et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012, 97:1882-1889.
-
(2012)
Haematologica
, vol.97
, pp. 1882-1889
-
-
Pidala, J.1
Kim, J.2
Jim, H.3
Kharfan-Dabaja, M.A.4
Nishihori, T.5
Fernandez, H.6
-
26
-
-
0034727833
-
Genomic aberrations and survival in chronic lymphocytic leukemia
-
Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
-
(2000)
N Engl J Med
, vol.343
, pp. 1910-1916
-
-
Dohner, H.1
Stilgenbauer, S.2
Benner, A.3
Leupolt, E.4
Krober, A.5
Bullinger, L.6
-
27
-
-
23944440464
-
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
-
Sorror M.L., Maris M.B., Storb R., Baron F., Sandmaier B.M., Maloney D.G., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
-
(2005)
Blood
, vol.106
, pp. 2912-2919
-
-
Sorror, M.L.1
Maris, M.B.2
Storb, R.3
Baron, F.4
Sandmaier, B.M.5
Maloney, D.G.6
-
28
-
-
0029029246
-
1994 consensus conference on acute GVHD grading
-
Przepiorka D., Weisdorf D., Martin P., Klingemann H.G., Beatty P., Hows J., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
-
(1995)
Bone Marrow Transplant
, vol.15
, pp. 825-828
-
-
Przepiorka, D.1
Weisdorf, D.2
Martin, P.3
Klingemann, H.G.4
Beatty, P.5
Hows, J.6
-
29
-
-
59549096541
-
New classification of chronic GVHD: added clarity from the consensus diagnoses
-
Arora M., Nagaraj S., Witte J., DeFor T.E., MacMillan M., Burns L.J., et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009, 43:149-153.
-
(2009)
Bone Marrow Transplant
, vol.43
, pp. 149-153
-
-
Arora, M.1
Nagaraj, S.2
Witte, J.3
DeFor, T.E.4
MacMillan, M.5
Burns, L.J.6
-
31
-
-
33845382806
-
Nonparametric estimation from incomplete observations
-
Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
-
(1958)
J Am Stat Assoc
, vol.53
, pp. 457-481
-
-
Kaplan, E.L.1
Meier, P.2
-
32
-
-
0000120995
-
A class of K-sample tests for comparing the cumulative incidence of a competing risk
-
Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
-
(1988)
Ann Stat
, vol.16
, pp. 1141-1154
-
-
Gray, R.J.1
-
33
-
-
1542532754
-
A proportional hazards model for the subdistribution of a competing risk
-
Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
-
(1999)
J Am Stat Assoc
, vol.94
, pp. 496-509
-
-
Fine, J.P.1
Gray, R.J.2
-
35
-
-
35548984981
-
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
-
Brunstein C.G., Barker J.N., Weisdorf D.J., DeFor T.E., Miller J.S., Blazar B.R., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110:3064-3070.
-
(2007)
Blood
, vol.110
, pp. 3064-3070
-
-
Brunstein, C.G.1
Barker, J.N.2
Weisdorf, D.J.3
DeFor, T.E.4
Miller, J.S.5
Blazar, B.R.6
-
36
-
-
0033008061
-
Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection
-
Thiede C., Florek M., Bornhauser M., Ritter M., Mohr B., Brendel C., et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999, 23:1055-1060.
-
(1999)
Bone Marrow Transplant
, vol.23
, pp. 1055-1060
-
-
Thiede, C.1
Florek, M.2
Bornhauser, M.3
Ritter, M.4
Mohr, B.5
Brendel, C.6
-
37
-
-
77957743452
-
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
-
Dreger P., Dohner H., Ritgen M., Bottcher S., Busch R., Dietrich S., et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010, 116:2438-2447.
-
(2010)
Blood
, vol.116
, pp. 2438-2447
-
-
Dreger, P.1
Dohner, H.2
Ritgen, M.3
Bottcher, S.4
Busch, R.5
Dietrich, S.6
-
38
-
-
84873567955
-
Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome
-
Brown J.R., Kim H.T., Armand P., Cutler C., Fisher D.C., Ho V., et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 2013, 27:362-369.
-
(2013)
Leukemia
, vol.27
, pp. 362-369
-
-
Brown, J.R.1
Kim, H.T.2
Armand, P.3
Cutler, C.4
Fisher, D.C.5
Ho, V.6
-
39
-
-
80053901737
-
Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome
-
Khouri I.F., Bassett R., Poindexter N., O'Brien S., Bueso-Ramos C.E., Hsu Y., et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 2011, 117:4679-4688.
-
(2011)
Cancer
, vol.117
, pp. 4679-4688
-
-
Khouri, I.F.1
Bassett, R.2
Poindexter, N.3
O'Brien, S.4
Bueso-Ramos, C.E.5
Hsu, Y.6
-
40
-
-
33947312235
-
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia
-
Brown J.R., Kim H.T., Li S., Stephans K., Fisher D.C., Cutler C., et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2006, 12:1056-1064.
-
(2006)
Biol Blood Marrow Transplant
, vol.12
, pp. 1056-1064
-
-
Brown, J.R.1
Kim, H.T.2
Li, S.3
Stephans, K.4
Fisher, D.C.5
Cutler, C.6
-
41
-
-
27744549869
-
Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)
-
Caballero D., Garcia-Marco J.A., Martino R., Mateos V., Ribera J.M., Sarra J., et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 2005, 11:7757-7763.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 7757-7763
-
-
Caballero, D.1
Garcia-Marco, J.A.2
Martino, R.3
Mateos, V.4
Ribera, J.M.5
Sarra, J.6
-
42
-
-
84866334906
-
Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia
-
Jaglowski S.M., Ruppert A.S., Heerema N.A., Bingman A., Flynn J.M., Grever M.R., et al. Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia. Br J Haematol 2012, 159:82-87.
-
(2012)
Br J Haematol
, vol.159
, pp. 82-87
-
-
Jaglowski, S.M.1
Ruppert, A.S.2
Heerema, N.A.3
Bingman, A.4
Flynn, J.M.5
Grever, M.R.6
-
43
-
-
84863468105
-
Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort
-
Toze C.L., Dalal C.B., Nevill T.J., Gillan T.L., Abou Mourad Y.R., Barnett M.J., et al. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. Br J Haematol 2012, 158:174-185.
-
(2012)
Br J Haematol
, vol.158
, pp. 174-185
-
-
Toze, C.L.1
Dalal, C.B.2
Nevill, T.J.3
Gillan, T.L.4
Abou Mourad, Y.R.5
Barnett, M.J.6
-
44
-
-
79960036578
-
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
-
Puente X.S., Pinyol M., Quesada V., Conde L., Ordonez G.R., Villamor N., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
-
(2011)
Nature
, vol.475
, pp. 101-105
-
-
Puente, X.S.1
Pinyol, M.2
Quesada, V.3
Conde, L.4
Ordonez, G.R.5
Villamor, N.6
-
45
-
-
84879173666
-
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
-
Dreger P., Schnaiter A., Zenz T., Bottcher S., Rossi M., Paschka P., et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood 2013, 121:3284-3288.
-
(2013)
Blood
, vol.121
, pp. 3284-3288
-
-
Dreger, P.1
Schnaiter, A.2
Zenz, T.3
Bottcher, S.4
Rossi, M.5
Paschka, P.6
-
46
-
-
63749116929
-
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes
-
van Besien K., Kunavakkam R., Rondon G., De Lima M., Artz A., Oran B., et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 2009, 15:610-617.
-
(2009)
Biol Blood Marrow Transplant
, vol.15
, pp. 610-617
-
-
van Besien, K.1
Kunavakkam, R.2
Rondon, G.3
De Lima, M.4
Artz, A.5
Oran, B.6
-
47
-
-
20544465644
-
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia
-
Sorror M.L., Maris M.B., Sandmaier B.M., Storer B.E., Stuart M.J., Hegenbart U., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005, 23:3819-3829.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3819-3829
-
-
Sorror, M.L.1
Maris, M.B.2
Sandmaier, B.M.3
Storer, B.E.4
Stuart, M.J.5
Hegenbart, U.6
-
48
-
-
38049141530
-
Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia
-
Sorror M.L., Storer B.E., Maloney D.G., Sandmaier B.M., Martin P.J., Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008, 111:446-452.
-
(2008)
Blood
, vol.111
, pp. 446-452
-
-
Sorror, M.L.1
Storer, B.E.2
Maloney, D.G.3
Sandmaier, B.M.4
Martin, P.J.5
Storb, R.6
|